Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing since 12/18/2024, newest first.
| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
RE/MAX Holdings, Inc.
13G
RMAX · 75524W108
|
4.7% |
8/20/2026
Event 8/13/2026
|
|||
| ExodusPoint Capital Management, LP | 4.7% | ||||
| ExodusPoint Capital Partners GP, LLC | 4.7% | ||||
| Michael Gelband | 4.7% | ||||
|
Spruce Biosciences, Inc.
13G
SPRB · 85209E208
|
0.8% |
4/28/2026
Event 4/22/2026
|
|||
| ExodusPoint Capital Management, LP | 0.8% | ||||
| ExodusPoint Capital Partners GP, LLC | 0.8% | ||||
| Michael Gelband | 0.8% | ||||
|
Keros Therapeutics, Inc.
13G/A
Amendment 1
KROS · 492327101
|
<0.1% |
2/17/2026
Event 12/31/2025
|
|||
| ExodusPoint Capital Management, LP | <0.1% | ||||
| ExodusPoint Capital Partners GP, LLC | <0.1% | ||||
| Michael Gelband | <0.1% | ||||
|
Keros Therapeutics, Inc.
13G
KROS · 492327101
|
6.3% |
11/18/2025
Event 11/10/2025
|
|||
| ExodusPoint Capital Management, LP | 6.3% | ||||
| ExodusPoint Capital Partners GP, LLC | 6.3% | ||||
| Michael Gelband | 6.3% | ||||
|
ALT5 Sigma Corp
13G
AIFC · 47089W104
|
4.8% |
8/18/2025
Event 8/11/2025
|
|||
| ExodusPoint Capital Management, LP | 4.8% | ||||
| ExodusPoint Capital Partners GP, LLC | 4.8% | ||||
| Michael Gelband | 4.8% | ||||
| Hyung Lee | 4.8% | ||||